Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 18/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5193828 | 0.88 | PYGL (0.60) | PYGLCYP2C9IDO1 | |
| SCHEMBL5191876 | 0.87 | PYGL (0.62) | PYGLCYP2C9IDO1 | |
| Hydrochloric Acid SCHEMBL5192284 | 0.86 | PYGL (0.61) | PYGLCYP2C9IDO1 | |
| SCHEMBL5195809 | 0.86 | PYGL (0.50) | PYGLCYP2C9IDO1 | |
| SCHEMBL5216655 | 0.85 | PYGL (0.38) | PYGLCYP2C9IDO1MMP1MMP2 | |
| SCHEMBL5423321 | 0.81 | PYGL (0.62) | PYGLCYP2C9IDO1 | |
| Hydrochloric Acid SCHEMBL5196178 | 0.80 | PYGL (0.59) | PYGLCYP2C9IDO1 | |
| Hydrochloric Acid SCHEMBL5211970 | 0.80 | PYGL (0.59) | PYGLCYP2C9 | |
| Hydrochloric Acid SCHEMBL5211974 | 0.80 | PYGL (0.59) | PYGLCYP2C9 | |
| Hydrochloric Acid SCHEMBL5211964 | 0.80 | PYGL (0.59) | PYGLCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | PYGL 2/4885CYP2C9 2982/4885IDO1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.